Company Overview and News

0
Lessons from the Energy Policy Development Program

2018-07-11 bworldonline
Next week, the Energy Policy Development Program (EPDP), a USAID-funded project implemented by the UP Economics Foundation, will have its last lecture and the launch of a book that incorporates conferences, lectures, and seminars the program has sponsored over the last four years.
FSGCF FGENG ABZPF FGENF FGEN FSGCY ABZPY AP

1
DoE expects LNG facility proposals by end 2018

2018-06-26 bworldonline
THE Department of Energy (DoE) expects to start receiving towards the end of the year firm proposals for an integrated facility for imported liquefied natural gas (LNG), an official said.
FSGCF FGENG FGENF FGEN FSGCY

27
Philippines' Phoenix Petroleum, China's CNOOC Partner For LNG Terminal

2018-06-05 rigzone
MANILA, June 5 (Reuters) - Philippine fuel retailer Phoenix Petroleum said it had agreed to partner with a subsidiary of state-owned China National Offshore Oil Corp (CNOOC) to explore building a receiving terminal for liquefied natural gas in the country.
RDS.B RDS.A PSKXF FSGCY RDSB RDSA FSGCF FGENG FGENF FGEN RYDBF PHSXY PSE RYDAF

20
First Gen eyes San Miguel as partner for proposed LNG import facility

2018-05-28 bworldonline
FIRST GEN Corp. is planning to invite diversified conglomerate San Miguel Corp. “within the year” to participate in its $1.2-billion liquefied natural gas (LNG) import facility, company officials said on Monday.
FSGCY SMCP1 SMGBY SMGBF FSGCF FGENG FGENF SMC2B SMC2A FGEN SMC SMC2D SMC2C SMC2F SMC2E

3
Lopez-led FPH sets P22-billion capex for 2018

2018-05-28 bworldonline
LOPEZ-LED First Philippine Holdings Corp. (FPH) is setting aside a budget of P22 billion for 2018, with its property development segment cornering the bulk of the capital expenditures, the company treasurer said on Monday.
FSGCF FGENG FGENF FGEN FSGCY FPH

21
SMC angles for role in First Gen’s LNG terminal

2018-05-16 bworldonline
SAN Miguel Corp. (SMC) said it is open to any form of tie-up with First Gen Corp. for the latter’s planned $1-billion liquefied natural gas (LNG) terminal.
FSGCY SMCP1 KEP SMGBY SMGBF FSGCF FGENG FGENF SMC2B SMC2A FGEN SMC SMC2D SMC2C SMC2F SMC2E

10
First Gen targets nearly $200M in recurring profit this year

2018-05-09 bworldonline
LOPEZ-LED First Gen Corp. expects its recurring net income in 2018 to reach nearly $200 million, an improvement over last year’s flat growth when two of its power plants were reporting losses.
FSGCF FGENG EGDCY FGENF MER FGEN FSGCY EDC 532219 ENERGYDEV

2
First Gen aims to select partners for LNG terminal within the year

2018-05-09 bworldonline
Lopez-led First Gen Corp. has set a firm schedule for its plan to build a liquefied natural gas (LNG) terminal and regasification facility, including the selection of a partner this year and the start of construction next year, company officials said.
FSGCF FGENG FGENF FGEN FSGCY LNG

47
Shares to decline amid weak investor sentiment

2018-05-06 bworldonline
LOCAL EQUITIES may continue to fall this week, as higher oil prices and faster inflation, among others, drag down investor sentiment.
EGDCY SMCP1 GTMEY 532219 RBLAY ENERGYDEV SMGBF FGENG FGENF SMC PHSXY GTMEF PSE GLOPA AYAAF PSKXF MWC FSGCY AYAAY GLOPP SMGBY FSGCF GLO SMC2B SMC2A FGEN SMC2D RLC SMC2C SMC2F SMC2E EDC ALI

2
Lopez Holdings 2017 profit down 36%

2018-04-17 business.inquirer.net
Conglomerate Lopez Holdings posted a net profit of P4.22 billion last year, down by 36 percent in the absence of one-off gains and election season-related surge in media advertising revenue that jacked up its bottom line in 2016.
FPHPC FSGCF FGENG FGENF FGEN FSGCY LPZ FPHP FPH

2
Lopez Holdings income declines 36% in 2017

2018-04-17 bworldonline
THE absence of one-time gains that inflated profits in 2016 dragged earnings Lopez Holdings, Inc. last year.
FPHPC FSGCF FGENG FGENF FGEN FSGCY LPZ FPHP FPH

2
Lopez Holdings 2017 profits down on lack of one-time gains

2018-04-17 bworldonline
The absence of one-time gains that inflated profits in 2016 dragged earnings of Lopez Holdings, Inc. last year.
FPHPC FSGCF FGENG FGENF FGEN FSGCY LPZ FPHP FPH

2
Lopez nets P4.2B

2018-04-17 business.inquirer.net
Conglomerate Lopez Holdings chalked up a net profit of P4.22 billion last year, down by 36 percent in the absence of one-off gains and election season-related surge in media advertising revenues that jacked up earnings in 2016.
FPHPC FSGCF FGENG FGENF FGEN FSGCY FPHP FPH

8
First Philippine Holding 2017 recurring profit up 15%

2018-04-06 bworldonline
FIRST Philippine Holdings Corp. (FPH) reported on Friday a 15% increase in 2017 net profit on a recurring basis to P6.8 billion, which excludes a one-off item in connection with debt prepayments by unit First Gen Corp.
FPHPC EGDCY FSGCY 532219 FPHP ENERGYDEV FSGCF FGENG FGENF FGEN EDC FPH

4
First Gen aims to secure more supply deals

2018-04-03 bworldonline
FIRST GEN Corp. is aiming to secure power supply contracts for 92% of the capacity it generates this year, an improvement over the 80% it recorded last year, the Lopez-led company told the stock exchange.
FSGCF FGENG FGENF MER FGEN FSGCY

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 320326101